Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Hartman

Showing results (441-450 of 459) with videos related to

Pageof 46
Sort By:
Chemmedchem|December 31, 2013
Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomniaAnthony J Roecker, Swati P Mercer, John D Schreier, et al.
Bioorganic & Medicinal Chemistry Letters|July 19, 2001
Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferaseD C Beshore, I M Bell, C J Dinsmore, et al.
Journal of Medicinal Chemistry|August 25, 2001
Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potencyI M Bell, S N Gallicchio, M Abrams, et al.
Journal of Medicinal Chemistry|October 17, 2003
Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosisJohn H Hutchinson, Wasyl Halczenko, Karen M Brashear, et al.
Journal of Medicinal Chemistry|November 30, 2004
Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channelMark T Bilodeau, Adrienne E Balitza, Timothy J Koester, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSPRobert M Garbaccio, Edward S Tasber, Lou Anne Neilson, et al.
Journal of Medicinal Chemistry|June 27, 2008
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancerChristopher D Cox, Paul J Coleman, Michael J Breslin, et al.
Chemmedchem|February 7, 2012
Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting propertiesPaul J Coleman, John D Schreier, Christopher D Cox, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2014
Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomniaAnthony J Roecker, Thomas S Reger, M Christa Mattern, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodentsZhi-Qiang Yang, Kelly-Ann S Schlegel, Youheng Shu, et al.
Pageof 46

Showing results (441-450 of 459) with videos related to

Sort By:
Pageof 46
Chemmedchem|December 31, 2013
Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomniaAnthony J Roecker, Swati P Mercer, John D Schreier, et al.
Bioorganic & Medicinal Chemistry Letters|July 19, 2001
Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferaseD C Beshore, I M Bell, C J Dinsmore, et al.
Journal of Medicinal Chemistry|August 25, 2001
Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potencyI M Bell, S N Gallicchio, M Abrams, et al.
Journal of Medicinal Chemistry|October 17, 2003
Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosisJohn H Hutchinson, Wasyl Halczenko, Karen M Brashear, et al.
Journal of Medicinal Chemistry|November 30, 2004
Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channelMark T Bilodeau, Adrienne E Balitza, Timothy J Koester, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSPRobert M Garbaccio, Edward S Tasber, Lou Anne Neilson, et al.
Journal of Medicinal Chemistry|June 27, 2008
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancerChristopher D Cox, Paul J Coleman, Michael J Breslin, et al.
Chemmedchem|February 7, 2012
Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting propertiesPaul J Coleman, John D Schreier, Christopher D Cox, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2014
Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomniaAnthony J Roecker, Thomas S Reger, M Christa Mattern, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodentsZhi-Qiang Yang, Kelly-Ann S Schlegel, Youheng Shu, et al.
Pageof 46